20
Participants
Start Date
March 31, 2006
Primary Completion Date
December 31, 2010
Study Completion Date
March 31, 2011
Infliximab
Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg
Placebo Comparator
Placebo administered in place of infliximab for control group
University of Pennsylvania, Philadelphia
Duke University Medical Center, Durham
University of Iowa Hospitals and Clinics, Iowa City
Norris Cancer Center, University of Southern California, Los Angeles
Autoimmunity Centers of Excellence
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH